Literature DB >> 26926647

Results from Oritavancin Resistance Surveillance Programs (2011 to 2014): Clarification for Using Vancomycin as a Surrogate To Infer Oritavancin Susceptibility.

Ronald N Jones1, Greg Moeck2, Francis F Arhin2, Michael N Dudley3, Paul R Rhomberg4, Rodrigo E Mendes4.   

Abstract

Measurement of vancomycin susceptibility has been shown to be highly predictive as a surrogate measure of oritavancin susceptibility among clinically indicated Gram-positive species. Results of studying over 30,000 pathogens (from 2011 to 2014) by cross-susceptibility analysis and determining the poor reproducibility of oritavancin-nonsusceptible results showed nearly perfect surrogate testing accuracy (99.86 to 99.94%). Any isolate of an indicated organism species with locally reproducible oritavancin-nonsusceptible results (extremely rare) should be referred to a reference laboratory for confirmation of the results and determination of the resistance mechanism.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26926647      PMCID: PMC4862529          DOI: 10.1128/AAC.03029-15

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  20 in total

1.  Factors influencing broth microdilution antimicrobial susceptibility test results for dalbavancin, a new glycopeptide agent.

Authors:  Robert P Rennie; Laura Koeth; Ronald N Jones; Thomas R Fritsche; Cindy C Knapp; Scott B Killian; Beth P Goldstein
Journal:  J Clin Microbiol       Date:  2007-08-01       Impact factor: 5.948

Review 2.  Oritavancin: A Long-Half-Life Lipoglycopeptide.

Authors:  Louis D Saravolatz; Gary E Stein
Journal:  Clin Infect Dis       Date:  2015-04-21       Impact factor: 9.079

3.  Comparative in vitro activity of oritavancin against recent, genetically diverse, community-associated meticillin-resistant Staphylococcus aureus (MRSA) isolates.

Authors:  Francis F Arhin; Natalia Kurepina; Ingrid Sarmiento; Thomas R Parr; Gregory Moeck; Barry Kreiswirth
Journal:  Int J Antimicrob Agents       Date:  2009-09-09       Impact factor: 5.283

4.  In vitro activities of LY333328 and comparative agents against nosocomial gram-positive pathogens collected in a 1997 global surveillance study.

Authors:  M L Zeckel; D A Preston; B S Allen
Journal:  Antimicrob Agents Chemother       Date:  2000-05       Impact factor: 5.191

5.  Semisynthetic glycopeptide antibiotics derived from LY264826 active against vancomycin-resistant enterococci.

Authors:  T I Nicas; D L Mullen; J E Flokowitsch; D A Preston; N J Snyder; M J Zweifel; S C Wilkie; M J Rodriguez; R C Thompson; R D Cooper
Journal:  Antimicrob Agents Chemother       Date:  1996-09       Impact factor: 5.191

6.  In vivo activity of oritavancin in animal infection models and rationale for a new dosing regimen in humans.

Authors:  Paul G Ambrose; George L Drusano; William A Craig
Journal:  Clin Infect Dis       Date:  2012-04       Impact factor: 9.079

7.  Unmet needs and prospects for oritavancin in the management of vancomycin-resistant enterococcal infections.

Authors:  Cesar A Arias; Rodrigo E Mendes; Matthew G Stilwell; Ronald N Jones; Barbara E Murray
Journal:  Clin Infect Dis       Date:  2012-04       Impact factor: 9.079

8.  Single-dose oritavancin versus 7-10 days of vancomycin in the treatment of gram-positive acute bacterial skin and skin structure infections: the SOLO II noninferiority study.

Authors:  G Ralph Corey; Samantha Good; Hai Jiang; Greg Moeck; Matthew Wikler; Sinikka Green; Paul Manos; Richard Keech; Rajesh Singh; Barry Heller; Natalia Bubnova; William O'Riordan
Journal:  Clin Infect Dis       Date:  2014-10-06       Impact factor: 9.079

9.  In vitro activity and spectrum of LY333328, a novel glycopeptide derivative.

Authors:  R N Jones; M S Barrett; M E Erwin
Journal:  Antimicrob Agents Chemother       Date:  1997-02       Impact factor: 5.191

10.  Single-dose oritavancin in the treatment of acute bacterial skin infections.

Authors:  G Ralph Corey; Heidi Kabler; Purvi Mehra; Sandeep Gupta; J Scott Overcash; Ashwin Porwal; Philip Giordano; Christopher Lucasti; Antonio Perez; Samantha Good; Hai Jiang; Greg Moeck; William O'Riordan
Journal:  N Engl J Med       Date:  2014-06-05       Impact factor: 91.245

View more
  7 in total

Review 1.  Targeting fundamental pathways to disrupt Staphylococcus aureus survival: clinical implications of recent discoveries.

Authors:  Isaac P Thomsen; George Y Liu
Journal:  JCI Insight       Date:  2018-03-08

2.  Evaluation of Non-Tissue Culture- versus Tissue Culture-Treated Microplates for Oritavancin Susceptibility Testing.

Authors:  Qun Yan; Melissa J Karau; Robin Patel
Journal:  J Clin Microbiol       Date:  2018-03-26       Impact factor: 5.948

Review 3.  Antimicrobial Susceptibility Testing for Enterococci.

Authors:  Ayesha Khan; William R Miller; Dierdre Axell-House; Jose M Munita; Cesar A Arias
Journal:  J Clin Microbiol       Date:  2022-06-13       Impact factor: 11.677

Review 4.  New Perspectives on Antimicrobial Agents: Long-Acting Lipoglycopeptides.

Authors:  Truc T Tran; Sara Gomez Villegas; Samuel L Aitken; Susan M Butler-Wu; Alex Soriano; Brian J Werth; Jose M Munita
Journal:  Antimicrob Agents Chemother       Date:  2022-04-27       Impact factor: 5.938

Review 5.  Recent Advances in the Development of Semisynthetic Glycopeptide Antibiotics: 2014-2022.

Authors:  Emma van Groesen; Paolo Innocenti; Nathaniel I Martin
Journal:  ACS Infect Dis       Date:  2022-07-27       Impact factor: 5.578

6.  Design and Preclinical Development of a Phage Product for the Treatment of Antibiotic-Resistant Staphylococcus aureus Infections.

Authors:  Susan M Lehman; Gillian Mearns; Deborah Rankin; Robert A Cole; Frenk Smrekar; Steven D Branston; Sandra Morales
Journal:  Viruses       Date:  2019-01-21       Impact factor: 5.048

7.  Oritavancin for the treatment of complicated gram-positive infection in persons who inject drugs.

Authors:  Aileen Ahiskali; Heather Rhodes
Journal:  BMC Pharmacol Toxicol       Date:  2020-10-28       Impact factor: 2.483

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.